产品
编 号：F571819
分子式：C16H17F2N3O3S
分子量：369.39
分子式：C16H17F2N3O3S
分子量：369.39
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 502887-71-0
产品详情
生物活性：
MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs.
体内研究：
MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor. MMP-9-IN-1 inhibits cancer cell metastasis in vivo.Animal Model:4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor
Dosage:20 mg/kg
Administration:Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks,
Result:Resulted in a profound delay in tumor growth.Inhibited cancer cell metastasis.
体外研究：
MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity.MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells.
MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs.
体内研究：
MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor. MMP-9-IN-1 inhibits cancer cell metastasis in vivo.Animal Model:4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor
Dosage:20 mg/kg
Administration:Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks,
Result:Resulted in a profound delay in tumor growth.Inhibited cancer cell metastasis.
体外研究：
MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity.MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备